Near the end of the year, financing events in the pharmaceutical field are also relatively frequent
.
According to combing, a number of huge financing events occurred in the pharmaceutical field in December, involving enterprises including Huaxian Pharmaceutical, Guoxin Pharmaceutical and other pharmaceutical companies
.
On December 16, Huaxian Pharmaceutical announced that it has recently completed a B+ round of financing of more than 100 million yuan, which will be mainly used to build a R&D center in East China and expand new production capacity, accelerating the layout of business territory in the Yangtze River Delta region
.
Huaxian Pharmaceutical's round of financing was jointly led by Yueke Zhuxi (Yueke Group) and Tuowei Zhonghui, and Jiande High-speed Railway New Area Investment and Yueke Huaxian (Yueke Group) co-invested, and Yuanyuan Zhitong served as the exclusive financial advisor
for this transaction.
Among them, Yueke Group, the investor of this round, believes that the overall development trend of the CDMO industry is good, and the industry is showing a high prosperity
.
With the rise of global bio-tech, the CDMO track has shown a state of high prosperity, and the outsourcing rate has continued to increase, which is beneficial to emerging countries and regions such as China.
The proportion of emerging pharmaceutical companies in the R&D pipeline continues to increase, giving CDMO companies business opportunities
.
Based in the core area of the Guangdong-Hong Kong-Macao Greater Bay Area, relying on the team and independent research and development technology, Huaxian Pharmaceutical is optimistic about the company's growth
.
According to the data, Huaxian Pharmaceutical is a one-stop CRO & CDMO service platform enterprise, and the company relies on the core technologies in chiral synthesis, biological enzyme catalysis and continuous flow microchannels to develop high-difficulty characteristic APIs and intermediates
in the fields of anti-tumor, antiviral and anti-respiratory diseases.
News on December 13, clinical CRO company Guoxin Pharmaceutical announced the completion of nearly 100 million yuan Series B + financing
.
After the completion of this round of financing, Guoxin Pharmaceutical will continue to focus on and deepen the clinical research of innovative drugs in cutting-edge pipelines, deepen its business and technology, and continue to highlight its advantages
in the field of cell and gene therapy (CGT).
This round of B+ financing is another financing completed by Guosen Pharmaceutical in 2022 after obtaining Series B financing
from Puhua Capital and Jinhuifeng Investment in August 2021.
Guosen Pharmaceutical's current round of financing, the old shareholder Yoyin Medical Fund continued to increase its weight, and the industry investment institutions Guangzhou High-tech Zone Group Guangzhou Guoju Venture Capital, Shenzhen Qianhai Beizeng Assets, Zhongguancun Bank Science and Technology Finance Center, Ruize (Guangzhou) Investment Joint Investment
.
According to the data, Guoxin Pharmaceutical, as a domestic clinical CRO industry enterprise, focuses on providing overall solutions
for clinical research registration and application services for innovative drugs and new drugs of cell and gene therapy (CGT).
Since 2020, Guoxin Pharmaceutical has focused on clinical CRO services for innovative drugs, cell and gene therapy, and quickly built an innovative service transformation platform
integrating cell therapy, gene therapy, oncolytic virus, ADC and nucleic acid drugs.
In addition, Alternative Bio Limited ("Alternative Bio") today announced the completion of a multi-million dollar seed round to advance the development of
a drug pipeline and drug discovery platform to regulate protein translation activity.
The round was co-led by Sequoia China Seed Fund and Eight Roads in collaboration with F-Prime Capital
.
According to the data, Bystbio is a biotechnology company that develops new drugs targeting chemically modified processing enzymes that have not received sufficient attention in the field, and is currently promoting the development of drug pipelines and drug discovery platforms to regulate protein translation activity, and the first batch of developed drugs is expected to be applied in the treatment of malignant
tumors.
Brighticon recently completed hundreds of millions of yuan in Series C financing, led by Songhe Capital, with the lead investors of angel round, Pre A round, A round, B round and many other old shareholders participating in the investment
.
It is reported that Bricom Technology is an enterprise in the field of neurotechnology, focusing on providing solutions
for innovative research in neuroscience and the diagnosis, treatment and rehabilitation of clinical neurological diseases.
At present, there are three key product matrices: scientific research grade EEG acquisition and stimulation equipment, which is used in scientific research in biomedicine, psychology, neuroscience and other fields; Medical-grade EEG equipment, used in the diagnosis and monitoring of epilepsy, brain tumors, cerebrovascular diseases and other diseases; Minimally invasive implantation of brain-computer interface system is applied to clinical scenarios
such as refractory epilepsy treatment and neurological disease rehabilitation.
In order to further improve the bandwidth of EEG signal transmission and at the same time enable brain-computer interface technology to be applied to clinical practice, Bricom has developed a "minimally invasive implantation" brain-computer interface technology route for clinical scenarios such as refractory epilepsy and neurological disease rehabilitation
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
